Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CORALVILLE, Iowa, Feb. 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the closing of $86.25 million aggregate principal amount of 5.50% senior convertible notes due 2021...
-
CORALVILLE, Iowa, Feb. 04, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the pricing of $75.0 million aggregate principal amount of 5.50% senior convertible notes due...
-
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
-
CORALVILLE, Iowa, Dec. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
-
CORALVILLE, Iowa, Dec. 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), today announced that it has submitted a New Drug Application (NDA) under Section 505(b)(2) of the Federal Food,...
-
NORTH LIBERTY, Iowa, June 11, 2012 (GLOBE NEWSWIRE) -- KemPharm, Inc. today presented key preclinical findings from KP511, the Company's first-in-class oral hydromorphone prodrug, at the 2012...
-
NORTH LIBERTY, Iowa, May 22, 2012 (GLOBE NEWSWIRE) -- KemPharm, Inc. ("KemPharm"), a clinical-stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat...
-
NORTH LIBERTY, Iowa, Oct. 26, 2011 (GLOBE NEWSWIRE) -- KemPharm, Inc. today announced it plans to initiate development of its recently identified lead compound KP511, a first-in-class oral prodrug of...
-
NORTH LIBERTY, Iowa, Aug. 30, 2011 (GLOBE NEWSWIRE) -- KemPharm, Inc. ("KemPharm") today announced it plans to initiate development of its recently identified lead compound KP415, a first-in-class...